|MKC-1 (Code C2507)|
|Terms & Properties|
Preferred Name: MKC-1
Definition: An orally bioavailable, small-molecule, bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites inhibit tubulin polymerization, blocking the formation of the mitotic spindle, which may result in cell cycle arrest at the G2/M phase and apoptosis. In addition, this agent has been shown to inhibit the activities of the oncogenic kinase Akt, the mTOR pathway, and importin-beta, a protein essential to the transport of other proteins from the cytosol into the nucleus.
NCI-GLOSS Definition: A substance that is being studied in the treatment of cancer. It may prevent cancer cells from dividing. It belongs to the family of drugs called cell cycle inhibitors.
Display Name: MKC-1
NCI Metathesaurus Link: C0796487 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
External Source Codes:
|CAS Registry Number||125313-92-0 (see NLM ChemIDplus info)|
|FDA UNII Code||DNZ11VPY7Q|
|PDQ Closed Trial Search ID||486351|
|PDQ Open Trial Search ID||486351 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
Additional Concept Data:
|Defined Fully by Roles: No|